Date: 2015-03-17
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Valneva (France- Austria) Jianshun Biosciences (China)
Therapeutic area: Infectious diseases - Veterinary medicine
Type agreement: licensing
Action mechanism: EB66® cell line is a highly efficient platform for vaccine production. It is derived from duck embryonic stem cells and today represents a compelling alternative to the use of chicken eggs for large scale manufacturing of human and veterinary vaccines. To date, Valneva has more than 35 research and commercial agreements with the world’s largest pharmaceutical companies to utilize its EB66® technology. The first human vaccine using EB66® technology received marketing approval in 2014 and the first veterinary vaccine in 2012.
Disease: human and veterinary vaccines
Details: * On March 17, 2015, Valneva SE, a leading pure play vaccines biotech company, announced that it has signed an exclusive license agreement with the Chinese company Jianshun Biosciences Ltd to commercialize Valneva’s EB66® cell line for the manufacturing of human and veterinary vaccines in People’s Republic of China only.
The Partner, Jianshun Biosciences Ltd, headquartered in Lanzhou (People’s Republic of China), provides bio process and technology services for Chinese biopharmaceutical companies. Dr. Luo Shun, Founder and President of the company, is one of the \"thousand people plan\"2 experts (thousands of foreign experts, or returning-Chinese talents) who have been nominated by the Central Government to work in China and promote innovation and technological development primarily in the high-tech and financial industries. Dr. Luo Shun worked in the USA for Amgen and for Genentech.
Under the terms of the agreement, Jianshun Biosciences Ltd is granted rights tovbsublicense Valneva’s EB66® cell line to Chinese vaccine companies which will then bebable to develop, manufacture and commercialize, in the People’s Republic of China Territory only, human and veterinary viral vaccines using the EB66® cell line. All vaccines against influenza for use in humans are excluded from the license agreement. Valneva remains the full owner of the EB66® platform and will continue to license its technology outside China.
Financial terms: Valneva will receive an upfront license payment of € 2.5 million and an additional payment of € 0.5 million in 2016, as well as annual maintenance fees and 50% of total revenues payable to Jianshun Biosciences Ltd from its sub licensees. These payments should contribute to further improve the profitability of the EB66® cell line in the coming years.
Latest news:
